Alnylam Pharma (DUL) Stock Statistics & Valuation Metrics

Alnylam Pharma has a market cap or net worth of $28.69B. The enterprise value is €30.43B.

Alnylam Pharma has 130,074,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Alnylam Pharma’s return on equity (ROE) is -4.15 and return on invested capital (ROIC) is -8.88%.

The current PE Ratio of Alnylam Pharma is -108.78. Alnylam Pharma’s PEG ratio is 2.82.

In the last 12 months, Alnylam Pharma had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.

In the last 12 months, operating cash flow was -8.31M and capital expenditures -34.28M, giving a free cash flow of -42.59M billion.

Alnylam Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Alnylam Pharma upcoming earnings date is May 1, 2025, TBA Not Confirmed.

Alnylam Pharma as a current ratio of 2.78, with Debt / Equity ratio of 1931.86%

In the past 12 months, Alnylam Pharma has paid 99.22M in taxes.

Alnylam Pharma EV to EBITDA ratio is -175.72, with an EV/FCF ratio of -737.92.

Alnylam Pharma has $2.69B in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.40B billion.

Gross margin is 85.62%, with operating margin of -7.87%, and net profit margin of -12.37%.

The average price target for Alnylam Pharma is $274.36, which is 11.43% higher than the current price. The consensus rating is Strong Buy